1. Paik JM, Kabbara K, Eberly KE, Younossi Y, Henry L, Younossi ZM. Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology. May 2022;75(5):1204-1217. doi:10.1002/hep.32228
2. Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. Jun 2019;16(6):377-386. doi:10.1038/s41575-019-0144-8
3. Lim GEH, Tang A, Ng CH, et al. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. Dec 4 2021;doi:10.1016/j.cgh.2021.11.038
4. Tang ASP, Chan KE, Quek J, et al. Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals. Clin Mol Hepatol. 7 2022;28(3):483-496. doi:10.3350/cmh.2021.0406
5. Yong JN, Ng CH, Lee CW-M, et al. Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. Hepatology International. 2022/04/01 2022;16(2):269-281. doi:10.1007/s12072-022-10319-6
6. Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. The Lancet Oncology. 2022;23(4):521-530. doi:10.1016/S1470-2045(22)00078-X
7. Toh JZK, Pan X-H, Tay PWL, et al. A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology. 2021;
8. Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. Apr 2020;72(4):785-801. doi:10.1016/j.jhep.2020.01.013
9. Le MH, Yeo YH, Li X, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 2021/12/07/ 2021;doi:https://doi.org/10.1016/j.cgh.2021.12.002
10. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. Oct 2017;67(4):862-873. doi:10.1016/j.jhep.2017.06.003
11. Tang A, Ng CH, Phang PH, et al. Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs. Non-Lean NAFLD - A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2022.06.029
12. Lear SA, Humphries KH, Kohli S, Chockalingam A, Frohlich JJ, Birmingham CL. Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT). Am J Clin Nutr. Aug 2007;86(2):353-9. doi:10.1093/ajcn/86.2.353
13. van der Poorten D, Milner K-L, Hui J, et al. Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48(2):449-457. doi:https://doi.org/10.1002/hep.22350
14. Basaranoglu M, Basaranoglu G, Bugianesi E. Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr. Apr 2015;4(2):109-16. doi:10.3978/j.issn.2304-3881.2014.11.05
15. Ng CH, Lim WH, Hui Lim GE, et al. Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. May 2 2022;doi:10.1016/j.cgh.2022.04.014
16. Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. May 2019;4(5):389-398. doi:10.1016/s2468-1253(19)30039-1
17. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterology. 2014;5(3):211-218. doi:10.1136/flgastro-2013-100403
18. Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut. 2010;59(7):861-866. doi:10.1136/gut.2010.214650
19. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. Journal of Hepatology. 2013/05/01/ 2013;58(5):1007-1019. doi:https://doi.org/10.1016/j.jhep.2012.11.021
20. American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2020;44(Supplement_1):S15-S33. doi:10.2337/dc21-S002
21. Caussy C, Alquiraish MH, Nguyen P, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology. 2018;67(4):1348-1359. doi:https://doi.org/10.1002/hep.29639
22. Petroff D, Blank V, Newsome PN, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. The Lancet Gastroenterology & Hepatology. 2021;6(3):185-198. doi:10.1016/S2468-1253(20)30357-5
23. Ziol M, Handra‐Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48-54.
24. Friedrich–Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134(4):960-974. e8.
25. Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol. Oct 21 2020;26(39):5919-5943. doi:10.3748/wjg.v26.i39.5919
26. Ng CH, Wong ZY, Chew NWS, et al. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Original Research. Frontiers in Cardiovascular Medicine. 2022-August-08 2022;9doi:10.3389/fcvm.2022.942753
27. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. Jan 10 2004;363(9403):157-63. doi:10.1016/s0140-6736(03)15268-3
28. Natekin A, Knoll A. Gradient boosting machines, a tutorial. Methods. Frontiers in Neurorobotics. 2013-December-04 2013;7doi:10.3389/fnbot.2013.00021
29. Weller BE, Bowen NK, Faubert SJ. Latent Class Analysis: A Guide to Best Practice. Journal of Black Psychology. 2020/05/01 2020;46(4):287-311. doi:10.1177/0095798420930932
30. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. Aug 2020;5(8):739-752. doi:10.1016/s2468-1253(20)30077-7
31. Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. Apr 2020;5(4):362-373. doi:10.1016/s2468-1253(19)30383-8
32. Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non-specialist needs to know. Diabetes, Obesity and Metabolism. 2022;24(S2):3-14. doi:https://doi.org/10.1111/dom.14521
33. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. Jun 2016;59(6):1121-40. doi:10.1007/s00125-016-3902-y
34. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. May 2022;28(5):528-562. doi:10.1016/j.eprac.2022.03.010
35. Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Research Support, Non-U.S. Gov't. Gut. 02 2022;71(2):382-390. doi:https://dx.doi.org/10.1136/gutjnl-2020-322564
36. Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology. Jul 13 2022;doi:10.1053/j.gastro.2022.06.023
37. Luukkonen PK, Qadri S, Ahlholm N, et al. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. Mar 2022;76(3):526-535. doi:10.1016/j.jhep.2021.10.013
38. Lee GH, Phyo WW, Loo WM, et al. Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population. World J Hepatol. Dec 27 2020;12(12):1228-1238. doi:10.4254/wjh.v12.i12.1228